Aceclofenac - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Aceclofenac

The Experts below are selected from a list of 3753 Experts worldwide ranked by ideXlab platform

Aceclofenac – Free Register to Access Experts & Abstracts

Lr Gupta – One of the best experts on this subject based on the ideXlab platform.

  • Simultaneous Spectrophotometric Estimation of Diacerein and Aceclofenac by Vierodt’s Method and First Derivative Method
    Asian Journal of Research in Chemistry, 2010
    Co-Authors: Sb Bhalerao, Tambe, Pareek, Rh Shinde, Lr Gupta
    Abstract:

    Two novel Spectrophotometric methods, simultaneous equation method (Vierodt’s Method) and first derivative method were developed, validated and compared for the simultaneous estimation of diacerein and Aceclofenac in their combined tablet dosage form. In Vierodt’s method, λ max of diacerein and Aceclofenac, 257.6 nm and 274.0 nm respectively were selected for estimation. In first derivative spectrophotometric method the zero crossing technique was applied for the estimation of diacerein and Aceclofenac in which 250.0 nm and 298.40 nm were selected respectively. The diacerein and Aceclofenac follow Beer-Lambert’s law in the concentration ranges from 2.5 to 15μg/mL and 5.0 to 30μg/mL respectively. The correlation coefficient was found to be 0.9998 for diacerein and 0.9998 for Aceclofenac by Vierodt’s method. By First Derivative method, correlation coefficient was found to be 0.9999 for diacerein and 0.9985 for Aceclofenac. Mean recoveries were found satisfactory. These procedures do not involve any separation step. Proposed methods were successfully applied for the simultaneous estimation of diacerein and Aceclofenac in the combined tablet dosage forms.

Ashwini Nangia – One of the best experts on this subject based on the ideXlab platform.

  • Solubility and Stability Advantage of Aceclofenac Salts
    Crystal Growth & Design, 2013
    Co-Authors: N. Rajesh Goud, Kuthuru Suresh, Ashwini Nangia
    Abstract:

    The nonsteroidal anti-inflammatory drug Aceclofenac was screened with pharmaceutically acceptable coformers to discover novel solid forms of improved solubility. First, the X-ray crystal structure of Aceclofenac (ACF) was analyzed to contain the rare carboxylic acid catemer O–H···O synthon, stabilized by auxiliary C–H···O and Cl···O interactions. Slurry grinding of Aceclofenac with different coformers in a fixed stoichiometry resulted in salts with cytosine (1:1), piperazine (1:0.5), l-lysilysine (1:1), and γ-aminobutyric acid (1:1). The problem of drug cyclization to give the inactive indolinone byproduct is avoided in the mild conditions of salt formation. All the salts were characterized by spectroscopic methods, thermal analysis, and X-ray diffraction. Aceclofenacl-lysilysine salt showed 135 times faster intrinsic dissolution rate (IDR) and 127 times higher area under the curve (AUC) compared to Aceclofenac. ACF–LYS is a high solubility salt that is stable in the accelerated International Conference on Harmo…

  • Solubility and Stability Advantage of Aceclofenac Salts
    , 2013
    Co-Authors: Rajesh N. Goud, Kuthuru Suresh, Ashwini Nangia
    Abstract:

    The nonsteroidal anti-inflammatory drug Aceclofenac was screened with pharmaceutically acceptable coformers to discover novel solid forms of improved solubility. First, the X-ray crystal structure of Aceclofenac (ACF) was analyzed to contain the rare carboxylic acid catemer O–H···O synthon, stabilized by auxiliary C–H···O and Cl···O interactions. Slurry grinding of Aceclofenac with different coformers in a fixed stoichiometry resulted in salts with cytosine (1:1), piperazine (1:0.5), l-lysilysine (1:1), and γ-aminobutyric acid (1:1). The problem of drug cyclization to give the inactive indolinone byproduct is avoided in the mild conditions of salt formation. All the salts were characterized by spectroscopic methods, thermal analysis, and X-ray diffraction. Aceclofenacl-lysilysine salt showed 135 times faster intrinsic dissolution rate (IDR) and 127 times higher area under the curve (AUC) compared to Aceclofenac. ACF–LYS is a high solubility salt that is stable in the accelerated International Conference on Harmonization (ICH) conditions of 40 °C and 75% relative humidity for 8 months

Sb Bhalerao – One of the best experts on this subject based on the ideXlab platform.

  • Simultaneous Spectrophotometric Estimation of Diacerein and Aceclofenac by Vierodt’s Method and First Derivative Method
    Asian Journal of Research in Chemistry, 2010
    Co-Authors: Sb Bhalerao, Tambe, Pareek, Rh Shinde, Lr Gupta
    Abstract:

    Two novel Spectrophotometric methods, simultaneous equation method (Vierodt’s Method) and first derivative method were developed, validated and compared for the simultaneous estimation of diacerein and Aceclofenac in their combined tablet dosage form. In Vierodt’s method, λ max of diacerein and Aceclofenac, 257.6 nm and 274.0 nm respectively were selected for estimation. In first derivative spectrophotometric method the zero crossing technique was applied for the estimation of diacerein and Aceclofenac in which 250.0 nm and 298.40 nm were selected respectively. The diacerein and Aceclofenac follow Beer-Lambert’s law in the concentration ranges from 2.5 to 15μg/mL and 5.0 to 30μg/mL respectively. The correlation coefficient was found to be 0.9998 for diacerein and 0.9998 for Aceclofenac by Vierodt’s method. By First Derivative method, correlation coefficient was found to be 0.9999 for diacerein and 0.9985 for Aceclofenac. Mean recoveries were found satisfactory. These procedures do not involve any separation step. Proposed methods were successfully applied for the simultaneous estimation of diacerein and Aceclofenac in the combined tablet dosage forms.

Kyung-mi Kim – One of the best experts on this subject based on the ideXlab platform.

  • Preparation and evaluation of Aceclofenac microemulsion for transdermal delivery system
    Archives of Pharmacal Research, 2002
    Co-Authors: Jae-heon Yang, Young-il Kim, Kyung-mi Kim
    Abstract:

    To develop novel transdermal formulation for Aceclofenac, microemulsion was prepared for increasing its skin permeability. Based on solubility and phase studies, oil and surfactant was selected and composition was determined. Microemulsion was spontaneously prepared by mixing ingredients and the physicochemical properties such was investigated. The mean diameters of microemulsion were approximately 90 nm and the system was physically stable at room temperature at least for 3 months. In addition, the in vitro and in vivo performance of microemulsion formulation was evaluated. Aceclofenac was released from microemulsion in acidic aqueous medium, and dissolved amounts of Aceclofenac was approximately 30% after 240 min. Skin permeation of Aceclofenac from microemulsion formulation was higher than that of cream. Following transdermal application of Aceclofenac preparation to delayed onset muscle soreness, serum creatine phosphokinase and lactate dehydrogenase activity was significantly reduced by Aceclofenac. Aceclofenac in microemulsion was more potent than cream in the alleviation of muscle pain. Therefore, the microemulsion formulation of Aceclofenac appear to be a reasonable transdermal delivery system of the drug with enhanced skin permeability and efficacy for the treatment of muscle damage.

Usha Y Nayak – One of the best experts on this subject based on the ideXlab platform.

  • a top down technique to improve the solubility and bioavailability of Aceclofenac in vitro and in vivo studies
    International Journal of Nanomedicine, 2017
    Co-Authors: Reema Narayan, Abhyuday Pednekar, Dipshikha Bhuyan, Chaitra Gowda, K B Koteshwara, Usha Y Nayak
    Abstract:

    The aim of the present work was to tackle the solubility issue of a biopharmaceutics classification system (BCS)-II drug, Aceclofenac. Although a number of attempts to increase the aqueous solubility have been made, none of the methods were taken up for scale-up. Hence size reduction technique by a top-down approach using wet milling process was utilized to improve the solubility and, consequently, the dissolution velocity of Aceclofenac. The quality of the final product was ensured by Quality by Design approach wherein the effects of critical material attributes and critical process parameters were assessed on the critical quality attributes (CQAs) of nanocrystals. Box-Behnken design was applied to evaluate these effects on critical quality attributes. The optimized nanocrystals had a particle size of 484.7±54.12 nm with a polydispersity index (PDI) of 0.108±0.009. The solid state characterization of the formulation revealed that the crystalline nature of the drug was slightly reduced after the milling process. With the reduced particle size, the solubility of the nanocrystals was found to increase in both water and 0.1 N HCl when compared with that of unmilled pure Aceclofenac. These results were further supported by in vitro release studies of nanocrystals where an appreciable dissolution velocity with 100.07%±2.38% release was observed for Aceclofenac nanocrystals compared with 47.66%±4.53% release for pure unmilled Aceclofenac at the end of 2 h. The in vivo pharmacokinetic data generated showed a statistically significant increase in the Cmax for Aceclofenac nanocrystals of 3.75±0.28 µg/mL (for pure unmilled Aceclofenac Cmax was 1.96±0.17 µg/mL). The results obtained indicated that the developed nanocrystals of Aceclofenac were successful in improving the solubility, thus the absorption and bioavailability of the drug. Hence, it may be a viable and cost-effective alternative to the current therapy.